Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation

Table 1 Analysis of clinical data

	SR + CHD	SR + VHD	PaAF + VHD	PeAF + VHD
Patient number	10	30	30	30
Sex, M/F (n)	4/6	16/14	13/17	12/18
Age (years)	16.20 ± 3.31	54.75 ± 3.68	55.61 ± 6.83	53.58 ± 4.63
Preoperative data
Heart rate (beats/min)	102.4 ± 4.51	79 ± 6.00	81 ± 7.00	83 ± 9.20
NYHA class I/II/III/IV	2/7/1/0	0/12/10/8	0/7/13/10	0/5/12/13
Echocardiographic parameters
LVDd	34 ± 2.30	53.55 ± 8.70	55.66 ± 14.13	54.97 ± 12.36
LVDs	24 ± 3.11	36.38 ± 1.26	39 ± 10.22	34.13 ± 11.03
EF (%)	64 ± 4.12	55.01 ± 4.80	53.08 ± 5.32	52.21 ± 5.21
LAD (mm)	23 ± 6.73	47.25 ± 5.19^c	55.43 ± 6.80^a,c	59.23 ± 5.92^b,c
RAD (mm)	27 ± 8.71	38.40 ± 5.20	38.10 ± 4.64	38.20 ± 5.00
Preoperative length of stay	10.00 ± 9.36	15.00 ± 1.80	16.00 ± 11.53	16.00 ± 13.40
Valve disease
Pure MVD	0	12	15	12
Mitral stenosis		4	5	6
Mitral regurgitation		5	6	2
Mitral stenoregurgitation		3	4	4
Pure AVD	0	10	6	5
Aortic valve stenosis		6	3	1
Aortic valve regurgitation		4	3	4
DVD	0	8	9	13
Preoperative drug
Digitalis	0	18	28	30
Diuretic	4	22	24	28
Nitrate drug	0	26	23	27
Calcium channel blocker	0	10	12	11
β-blocker	3	10	22	30
ACEI	0	19	21	18
Operative data
Surgical procedure
MVR/AVR/DVR	0/0/0	12/10/8	15/6/9	12/5/13
CPB duration	78 ± 11.44	130 ± 12.42	141 ± 23.44	145 ± 13.23
Aortic clamp time	45.32 ± 33.32	79 ± 34.43	82 ± 35.26	90 ± 42.13

Data are presented as n or mean ± standard deviation.
AVD, aortic valve disease; CHD, Congenital heart disease; DVD, Double valvular disease (mitral and aortic valves); MVD, Mitral valvular disease; PaAF, Paroxysmal atrial fibrillation; PeAF, Persistent atrial fibrillation; SR, Sinus rhythm; VHD, Valvular heart disease.
^aPaAF + VHD vs. SR + VHD; P < 0.01. ^bPeAF + VHD vs. SR + VHD; P < 0.01. ^cLAD vs. RAD; P < 0.01.

ISSN: 1471-2261